What is Hemopet?
Established in 1991, Hemopet operates the first private non-profit animal blood bank in the United States. The organization provides licensed, full-service blood components and supplies for transfusions to veterinary clinics across the country. Hemopet is dedicated to making transfusion medicine practical, safe, and affordable, prioritizing the quality and safety of its blood products and the comprehensive care of its donor animals. Their rigorous testing ensures donor blood is DEA 4 positive and negative for other known canine red blood cell antigens that can cause transfusion incompatibilities, positioning them as a trusted provider of canine blood products.
How much funding has Hemopet raised?
Hemopet has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Hemopet
PPP
Public-Private Partnership
What's next for Hemopet?
With its recent strategic investment and substantial overall capital, Hemopet is poised for continued growth and innovation in the veterinary field. The company's focus on safety, affordability, and donor care, coupled with its established infrastructure as a national supplier, suggests a trajectory aimed at further solidifying its market leadership. Future developments may include expanding service offerings, enhancing donor recruitment programs, and potentially exploring new technologies to optimize blood component delivery and efficacy for veterinary practices nationwide.
See full Hemopet company page
